# A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

> **NCT04757363** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 39 (actual)

## Conditions studied

- Esophagogastric Cancer
- HER2-Negative

## Interventions

- **DRUG:** regorafenib
- **DRUG:** nivolumab
- **DRUG:** FOLFOX chemotherapy with oxaliplatin

## Key facts

- **NCT ID:** NCT04757363
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-11
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04757363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04757363, "A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04757363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*